STATEN ISLAND, NY Two drugs have been recalled due to a major labeling mix-up, according to a recall notice from the U.S. Food and Drug Administration...
Continue reading...label
FDA approves supplemental new drug application to expand Mavacamten label for hypertrophic obstructive cardiomyopathy
The FDA has approved a supplemental new drug application (sNDA) to expand the label on mavacamten (Camzyos) to include data from the Phase 3 VALOR HCM...
Continue reading...